Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

Autor: P, Dávila-Seijo, E, Dauden, G, Carretero, C, Ferrandiz, F, Vanaclocha, F-J, Gómez-García, E, Herrera-Ceballos, P, De la Cueva-Dobao, I, Belinchón, J-L, Sánchez-Carazo, M, Alsina, J-L, López-Estebaranz, M, Ferrán, R, Torrado, J-M, Carrascosa, M, Llamas, R, Rivera, R, Jiménez-Puya, I, García-Doval, Sagrario Galiano, Mejías
Rok vydání: 2016
Předmět:
Zdroj: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
ISSN: 0926-9959
Popis: BackgroundFew reported studies compare drug survival in moderate-to-severe psoriasis vulgaris. ObjectivesTo describe and compare drug survival of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab and ustekinumab) and classical drugs (acitretin, ciclosporin and methotrexate) in moderate-to-severe psoriasis. MethodsThis was a multicenter, prospective, cohort study of patients receiving systemic therapies between 2008 and 2013 in 12 hospitals in Spain. Baseline data and drug discontinuation were collected. Drug survival is presented using Kaplan-Meier survival curves. We compared adjusted risk ratios of serious adverse events (AEs) with results of survival analysis for AEs. ResultsA total of 1956 patients were included for analysis (1240 exposed to biologics during follow-up and 1076 to classic therapies). Median follow-up time was 3.3 years (0.0-5.1 years). There were 2209 discontinuations out of 3640 therapy cycles started. The main reason for discontinuation was lack of efficacy (36.4%) and remission (27.2%). Biologics showed a higher drug survival than classics and the pattern of survival results for all outcomes (positive or negative) were very similar. Adjusted risk ratios of serious AEs did not agree with results of survival analysis. LimitationsA limitation is that this is an observational study with potential selection bias. ConclusionSurvival as a proxy measure of drug safety in psoriasis is inadequate.
Databáze: OpenAIRE
Externí odkaz: